Terlivaz is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Mallinckrodt Hospital Products Inc.. The primary component is Terlipressin.
Product ID | 43825-200_08efe631-e704-4997-a4f2-ac2131c051f1 |
NDC | 43825-200 |
Product Type | Human Prescription Drug |
Proprietary Name | Terlivaz |
Generic Name | Terlipressin |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2022-09-14 |
Marketing Category | NDA / |
Application Number | NDA022231 |
Labeler Name | Mallinckrodt Hospital Products Inc. |
Substance Name | TERLIPRESSIN |
Active Ingredient Strength | 1 mg/5mL |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2022-09-14 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
TERLIVAZ 98802165 not registered Live/Pending |
Mallinckrodt Pharmaceuticals Ireland Limited 2024-10-15 |
TERLIVAZ 97051486 not registered Live/Pending |
Mallinckrodt Hospital Products IP Limited 2021-09-29 |
TERLIVAZ 85876469 4720688 Live/Registered |
Ikaria Therapeutics LLC 2013-03-14 |